Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Biomed Pharmacother ; 88: 795-803, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28160754

RESUMO

Breast cancer is the most important cause of death in women globally. Though, improved survival is due to the developments in the screening techniques, initial diagnosis, and advances in treatments. Numerous factors contributed in the progression of breast cancer, such as inflammation. The most significant factor involved in the inflammatory process, is T helper 17 (Th17) cells. Th17 cells have an exceptional role in many of inflammatory diseases like psoriasis, rheumatoid arthritis, and breast cancer through production of proinflammatory cytokine (IL17). As the collected indication recommends a possible relevance between chronic inflammation and cancer tumorigenesis, it appears that this cytokine can stimulate the tumorigenesis of breast tumor cells. The IL17 family consist of 6 protein members, among them IL17B and its receptor, and IL17RB signaling pathway plays a key role in development and progression of breast cancer, and targeting this signaling pathway or its specific downstream mediators by a chemotherapy drug and small interfering RNA interference is a potentially novel therapeutic pathway for inhibition of this disease. This comprehensive review details the recognition of activity, signaling, and the roles of IL17B-IL17RB in breast cancer have caused to determination of new therapeutic mechanisms with the purpose of introduction this system and the regulation of its signaling pathway.


Assuntos
Neoplasias da Mama/genética , Interleucina-17/genética , Receptores de Interleucina/genética , Transdução de Sinais , Animais , Neoplasias da Mama/metabolismo , Feminino , Humanos , Inflamação/genética , Inflamação/metabolismo , Interleucina-17/metabolismo , Receptores de Interleucina/metabolismo , Receptores de Interleucina-17 , Células Th17/metabolismo
2.
Biomed Pharmacother ; 83: 229-240, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27372407

RESUMO

Overexpression of IL17RB is associated with poor prognosis and short survival of the breast cancer patients.IL17RB/IL17B signaling triggers a substantial increase in the cell growth, proliferation and migration through the activation of NF-κB as well as the up-regulation of the Bcl-2. In this study we designed carboxymethyl dextran (CMD) Chitosan nanoparticles (ChNPs) to encapsulated IL17RB siRNA and doxorubicin (DOX) as an anticancer drug. Then we investigated the efficiency of the simultaneous delivery of drug/siRNA on viability and gene expression of MDA-MB361 cell lines. Furthermore the efficacy of dual agent nanoparticles to induce apoptosis and inhibit migration of breast cancer cells was assessed by Annexin-V and wound healing assays respectively. Our results showed that DOX-siRNA-CMD-ChNPs had about 114nm size; with polydispersity index and zeta potential about 0.3 and 10.1mV respectively. Fourier transform infrared spectroscopy (FTIR) confirmed the formation of DOX-siRNA-CMD-ChNPs complex. In addition IL17RB siRNA had significant effect on DOX-induced cytotoxicity in MDA-MB361 cells. Furthermore treatment with dual agent nanoparticles resulted in a significant silencing of NF-κB and Bcl-2 relative gene expression, apoptosis induction and migration inhibition in MDA-MB361 cells. In conclusion, co-delivery of IL17RB siRNA and DOX can be considered as an effective system for the treatment of breast cancer.


Assuntos
Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Quitosana/análogos & derivados , Doxorrubicina/uso terapêutico , Sistemas de Liberação de Medicamentos , Nanopartículas/química , RNA Interferente Pequeno/metabolismo , Receptores de Interleucina-17/metabolismo , Antineoplásicos/farmacologia , Neoplasias da Mama/genética , Neoplasias da Mama/patologia , Morte Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Movimento Celular/efeitos dos fármacos , Quitosana/química , Doxorrubicina/farmacologia , Feminino , Citometria de Fluxo , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Heparina/metabolismo , Humanos , NF-kappa B/genética , NF-kappa B/metabolismo , Proteínas Proto-Oncogênicas c-bcl-2/genética , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Soro/metabolismo , Espectroscopia de Infravermelho com Transformada de Fourier , Cicatrização/efeitos dos fármacos
3.
Hum Antibodies ; 23(3-4): 73-9, 2015 Dec 23.
Artigo em Inglês | MEDLINE | ID: mdl-27472865

RESUMO

BACKGROUND: Tetanus neurotoxin (TeNT) is composed of a light (LC) and heavy chain (HC) polypeptides, released by anaerobic bacterium Clostridium tetani and can cause fatal life-threatening infectious disease. Toxin HC and LC modules represents receptor binding and zinc metalloprotease activity, respectively. The passive administration of animal-derived antibodies against tetanus toxin has been considered as the mainstay therapy for years. However, this treatment is associated with several adverse effects due to the presence of anti-isotype antibodies. OBJECTIVE: In the present study, we have produced the fully human single chain antibody fragments (HuScFv) from two human antibody phage display libraries. MATERIAL AND METHODS: Twenty-four different HuscFvs were isolated from two anti TeNT immune libraries. Our produced human ScFv (HuScFv) were converted to IgG platform and analyzed regarding their specific reactivity to TeNT. RESULTS: All of the selected scFvs have the same VL but different VH. Three HuscFvs from the first library (TTX15, 51, 75) and two HuscFvs from the second library (TTX16, 20) were chosen to convert to IgG1 using pOptiVEC and pcDNA3.3 systems. Production of IgG1 from transfected DG44 and binding capacity of them to tetanus toxin and toxoid were measured by ELISA. ELISA results showed no detectable production of TTX16 and TTX20 IgG1. Although, TTX51 and TTX75 were converted and produced as IgG1, no reactivity to tetanus toxin and toxoid was observed. However, TTX15 was successfully produced as whole IgG1 platform with reactivity to both tetanus toxin and toxoid. The latter would be an appropriate replacement for conventional polyclonal antibodies if would meet the further characterization including specificity determination, affinity measurement and toxin neutralizing assays. CONCLUSION: Our results demonstrated production of functional IgG1 derived from TTX15 scFv and might be an appropriate replacement for polyclonal Tetabulin but it needs further characterization.


Assuntos
Anticorpos Antibacterianos/biossíntese , Anticorpos Monoclonais/biossíntese , Imunoglobulina G/biossíntese , Biblioteca de Peptídeos , Anticorpos de Cadeia Única/biossíntese , Tétano/prevenção & controle , Anticorpos Antibacterianos/isolamento & purificação , Anticorpos Antibacterianos/farmacologia , Anticorpos Monoclonais/isolamento & purificação , Anticorpos Monoclonais/farmacologia , Linfócitos B/imunologia , Linfócitos B/microbiologia , Clostridium tetani/imunologia , Clostridium tetani/patogenicidade , Desenho de Fármacos , Ensaio de Imunoadsorção Enzimática , Humanos , Imunoglobulina G/isolamento & purificação , Imunoglobulina G/farmacologia , Metaloendopeptidases/antagonistas & inibidores , Metaloendopeptidases/química , Metaloendopeptidases/imunologia , Ligação Proteica , Engenharia de Proteínas , Anticorpos de Cadeia Única/isolamento & purificação , Anticorpos de Cadeia Única/farmacologia , Tétano/imunologia , Tétano/microbiologia , Toxina Tetânica/antagonistas & inibidores , Toxina Tetânica/química , Toxina Tetânica/imunologia , Toxoide Tetânico/antagonistas & inibidores , Toxoide Tetânico/química , Toxoide Tetânico/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA